Immune profiling links autoimmune hepatitis to human herpesvirus 6 and relaxin receptor antigens

Read full text
Authors: Arielle Klepper, James Asaki, Colette M. Caspar, Andrew F. Kung, Sara E. Vazquez, Aaron Bodansky, Anthea Mitchell, Sabrina A Mann, Kelsey C. Zorn, Isaac Avila-Vargas, Swathi Kari, Melawit Tekeste
+16 more Javier Castro, Briton Lee, Maria Duarte, Mandana Khalili, Monica Yang, Paul J. Wolters, Jennifer C. Price, Emily R. Perito, Sandy Feng, Jacquelyn J. Maher, Michael R. Wilson, Jennifer C. Lai, C Weiler-Normann, Ansgar W. Lohse, Joseph DeRisi, Michele Tana
Cited by: 2
References: 49

Abstract

Autoimmune hepatitis (AIH) is a severe, chronic disease where IgG elevation and autoantibody profile are defining features. However, linking autoantibodies to AIH pathogenesis remains elusive. We employed phage-display immunoprecipitation sequencing and uncovered a novel humoral signature specific to AIH. Embedded within this signature were antibodies against the known AIH autoantigen SLA/LP and novel reactivities to disco-interacting protein 2 homolog A (DIP2A), and the relaxin family peptide receptor 1 (RXFP1). Fine mapping of the DIP2A epitope revealed preferential enrichment for a nearly identical 9-amino acid sequence derived from the U27 protein of human herpesvirus 6 (HHV6). Preincubation with the HHV6 epitope blocked DIP2A binding, consistent with cross-reactivity. AIH patients positive for anti-DIP2A had higher titers of HHV6 IgG, suggestive of reactivation. AIH patients had antibodies against the antifibrotic receptor, RXFP1, which inhibited relaxin-2 signaling in an IgG-dependent manner. These data provide evidence for a novel serological profile in AIH, linking HHV6 reactivation anti-RXFP1 antibodies to disease pathogenesis.

Fields of Study & Subjects

Pregnancy-related medical research Liver Diseases and Immunity Spondyloarthritis Studies and Treatments

Publication details

Journal / source
The Journal of Experimental Medicine
Publisher
Rockefeller University Press
Volume
223
Issue
4
Publication date
9 January 2026
Language
EN